BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
On September 1st, BeiGene announced that the FDA has greenlit its Brukinsa (zanubrutinib), a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) for treating adult patients with a rare type of lymphoma called Waldenström’s macroglobulinemia (WM).
This is Brukinsa's second FDA approval, after bagging authorization from the agency for treating Mantle Cell Lymphoma in 2019. Besides the US, the drug has received marketing approval in five countries for this indication. Before the latest FDA approval, Brukinsa was approved for treating WM in China and Canada.
This is Brukinsa's second FDA approval, after bagging authorization from the agency for treating Mantle Cell Lymphoma in 2019. Besides the US, the drug has received marketing approval in five countries for this indication. Before the latest FDA approval, Brukinsa was approved for treating WM in China and Canada.
GO Prime with only $1.49 now
LATEST
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115